-
公开(公告)号:WO2022239959A1
公开(公告)日:2022-11-17
申请号:PCT/KR2022/004329
申请日:2022-03-28
申请人: (주)넥셀
IPC分类号: C12N5/077 , C12N5/071 , C12N2500/38 , C12N2501/115 , C12N2501/155 , C12N2501/16 , C12N2501/165 , C12N2501/415 , C12N2501/727 , C12N2506/02 , C12N2506/03 , C12N5/06 , C12N5/0656 , C12N5/0657 , C12N5/069 , C12N5/0697
摘要: 본 발명은 인간 전분화능 줄기세포 유래 심장 오가노이드 제조 방법에 관한 것으로, 인간 전분화능 줄기세포(hPSC, human Pluripotent Stem Cell)를 배양하여 100㎛ 내지 130㎛의 직경을 갖춘 배아체(Embryonic Body)를 마련하는 A단계; 상기 A단계를 통해 마련된 배아체를 200㎛ 내지 250㎛의 직경을 갖출 때까지 배양하는 B단계; 상기 B단계를 통해 200㎛ 내지 250㎛의 직경을 갖춘 인간 전분화능 줄기세포 유래 배아체를 중배엽 세포 및 내배엽 세포를 포함하는 구성체로 분화시키는 C단계; 상기 C단계를 통해 분화된 중배엽 세포 및 내배엽 세포를 포함하는 구성체를 심근세포(Cardiomyocyte), 섬유아세포(Fibroblast) 및 혈관내피세포(Endothelial Cell)를 포함하도록 자가조직화된 심장 오가노이드로 분화시키는 D단계; 및 상기 D단계를 통해 분화되어 자가조직화된 심장 오가노이드를 배양하여 성숙화시키는 E단계;를 포함하며, 상기 E단계를 통해 성숙화 과정을 거친 심장 오가노이드는 심근세포(Cardiomyocyte), 섬유아세포(Fibroblast) 및 혈관내피세포(Endothelial Cell)가 55 내지 65 : 15 내지 30 : 15의 세포수 비율로 자가조직화된 것을 특징으로 한다.
-
公开(公告)号:WO2021148516A1
公开(公告)日:2021-07-29
申请号:PCT/EP2021/051297
申请日:2021-01-21
发明人: LEI, Ming , TERRAR, Derek , AHMAD, Faizzan
IPC分类号: C12N5/077 , C12N2501/155 , C12N2501/385 , C12N2501/415 , C12N2506/45 , C12N5/0657
摘要: The present invention relates to a process for producing a population of cells which comprises mature atrial cardiomyocytes. The process comprises the step of treating iPS cells according to a treatment regimen which comprises contacting the iPS cellswith Gremlin2 and retinoic acid, such that at least a portion of the iPS cells differentiate into mature atrial cardiomyocytes.
-
公开(公告)号:WO2023287827A2
公开(公告)日:2023-01-19
申请号:PCT/US2022/036874
申请日:2022-07-12
发明人: SCHREPFER, Sonja , REBAR, Edward , GOLDMAN, Daniel
IPC分类号: C07K14/74 , C07K14/705 , C12N5/079 , C12N5/0783 , C12N5/071 , C12N5/077 , A61K35/17 , A61K35/30 , A61K35/34 , A61K35/39 , A61P37/06 , C07K14/70539 , C07K14/70596 , C12N5/0622 , C12N5/0636 , C12N5/0657 , C12N5/0676 , C12N5/0678
摘要: Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered cells and/or hypoimmunogenic stem cells, engineered cells and/or hypoimmunogenic cells differentiated therefrom, and engineered cells and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation comprising reduced expression of one or more Y chromosome genes and reduced expression of MHC I and/or MHC II human leukocyte antigen molecules and overexpression of CD47. Provided herein are cells further exhibiting reduced expression of T-cell receptors.
-
公开(公告)号:WO2022079272A1
公开(公告)日:2022-04-21
申请号:PCT/EP2021/078668
申请日:2021-10-15
IPC分类号: C12N5/00 , C12N5/077 , C12N5/071 , C12N2533/90 , C12N5/0012 , C12N5/0068 , C12N5/0657 , C12N5/0671
摘要: The invention relates to self-assembled peptide hydrogel spheroids, with a diameter of between 500 and 2500 µm, comprising cells encapsulated within said hydrogel. The invention further relates to in vitro methods of producing a hydrogel spheroid comprising cells, the method comprising: a) mixing a suspension of cells with a self-assembling peptide, and b) transferring an aliquot of the mixture obtained in step a) into an aqueous salt solution by applying a droplet of the mixture to the surface of the solution thereby forming a hydrogel spheroid comprising encapsulated cells, wherein the droplet has a volume of between 0,1 and 20 µl. and wherein the droplet comprises cells at a concentration of between 1 x 105 to 5 x 107 cells per ml solution.
-
公开(公告)号:WO2022013800A1
公开(公告)日:2022-01-20
申请号:PCT/IB2021/056384
申请日:2021-07-15
发明人: ZOUBI, Alaa , LEVY, Nakdimon Nissim , BAR-ON, Tal Haim , HAYAM, Gal , HAGLA, Wagdi Hani , ELIYAHU, Shiran , TURGEMAN, Aharon , MAYDEL, Michael , ITAH, Refael , BOTZER, Lior , KDOSHAI SCLIAR, Hen
IPC分类号: A61B5/28 , C12N5/077 , A61L27/3882 , A61N1/056 , A61N1/362 , A61N1/3787 , C12N2513/00 , C12N5/0657
摘要: A medical tool testing apparatus comprising a vessel. The vessel comprises a scaffold formed from biomaterial, live cardiac tissue, generated from cardiac cells, proliferating on the scaffold, the live cardiac tissue configured to generate electrical activity. The vessel also comprises a medical tool, in contact with live cardiac tissue, used for a medical procedure within patient anatomy. Operational features of the medical tool are determined by a visually perceptible condition of the live cardiac tissue.
-
公开(公告)号:WO2021146222A1
公开(公告)日:2021-07-22
申请号:PCT/US2021/013140
申请日:2021-01-12
发明人: DOWDLE, William , MAY, Andrew , SCHREPFER, Sonja
IPC分类号: C12N15/113 , C12N5/078 , C12N15/1137 , C12N2310/20 , C12N2510/00 , C12N5/0657 , C12Y204/01037 , C12Y204/0104 , C12Y204/01069
摘要: Provided herein are cells with a gene modification of an ABO gene, RED gene, and/or FUT1 gene. In some embodiments, the cells express reduced levels of a MHC I antigen and/or a MHC II antigen. In some instances, the cells are also hypoimmunogenic cells.
-
公开(公告)号:WO2021123682A1
公开(公告)日:2021-06-24
申请号:PCT/FR2020/052557
申请日:2020-12-18
申请人: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITE DE MONTPELLIER , ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , UNIVERSITE CLAUDE BERNARD LYON 1 , ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES , HOSPICES CIVILS DE LYON , DIAG'NCELL
IPC分类号: C12N5/077 , C12N5/071 , C12N2502/025 , C12N2502/28 , C12N2503/02 , C12N2506/45 , C12N2533/92 , C12N5/0657 , C12N5/0697
摘要: La présente invention a pour objet un modèle organoïde cardiaque vascularisé comprenant des cardiomyocytes dérivés de cellules souches pluripotentes induites humaines (hiPSC-CM) greffés sur une membrane chorio-allantoïde d'œuf fécondé. La présente invention a également pour objet un procédé d'obtention dudit modèle organoïde cardiaque vascularisé. La présente invention a également pour objet un procédé de caractérisation de l'activité d'un composé vis-à-vis du modèle organoïde cardiaque vascularisé. La présente invention a également pour objet un kit comprenant ledit modèle organoïde cardiaque vascularisé.
-
-
-
-
-
-